NextCure Faces Delisting Concerns
Ticker: NXTC · Form: 8-K · Filed: Feb 3, 2025 · CIK: 1661059
| Field | Detail |
|---|---|
| Company | Nextcure, Inc. (NXTC) |
| Form Type | 8-K |
| Filed Date | Feb 3, 2025 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
Related Tickers: NXTC
TL;DR
NextCure might get delisted, filing shows.
AI Summary
NextCure, Inc. filed an 8-K on February 3, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule as of January 31, 2025. The company, incorporated in Delaware, is based in Beltsville, Maryland.
Why It Matters
This filing indicates potential issues with NextCure's continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading and overall financial health.
Key Players & Entities
- NextCure, Inc. (company) — Registrant
- January 31, 2025 (date) — Date of earliest event reported
- February 3, 2025 (date) — Filing date
- Beltsville, Maryland (location) — Principal executive offices
FAQ
What specific listing rule or standard has NextCure, Inc. failed to satisfy?
The filing states it is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not specify which rule or standard has been violated.
What is the effective date of the delisting notice?
The earliest event reported is January 31, 2025, which is the date as of which the company is reporting its status regarding listing standards.
Has NextCure, Inc. transferred its listing?
The filing indicates 'Transfer of Listing' as a potential item, but the details of any such transfer are not provided in this excerpt.
What is NextCure, Inc.'s primary business?
NextCure, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry, SIC code 2834.
Where are NextCure, Inc.'s principal executive offices located?
The principal executive offices are located at 9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705.
Filing Stats: 782 words · 3 min read · ~3 pages · Grade level 12.5 · Accepted 2025-02-03 16:10:23
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share NXTC Nasdaq Glo
- $1.00 — secutive business days had fallen below $1.00 per share, which is the minimum average
Filing Documents
- nxtc-20250131x8k.htm (8-K) — 44KB
- 0001558370-25-000603.txt ( ) — 170KB
- nxtc-20250131.xsd (EX-101.SCH) — 4KB
- nxtc-20250131_def.xml (EX-101.DEF) — 3KB
- nxtc-20250131_lab.xml (EX-101.LAB) — 17KB
- nxtc-20250131_pre.xml (EX-101.PRE) — 11KB
- nxtc-20250131x8k_htm.xml (XML) — 5KB
01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 31, 2025, NextCure, Inc. (the "Company", "we", "us", or "our") received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq") notifying us that the closing price of our common stock over the prior 30 consecutive business days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have 180 calendar days, or until July 30, 2025, to regain compliance with the Minimum Bid Requirement (the "Grace Period"), subject to a potential 180 calendar day extension, as described below. To regain compliance, the closing bid price of our common stock must be at least $1.00 per share for a minimum of ten consecutive business days within the Grace Period. If we do not achieve compliance with the Minimum Bid Requirement by the end of the Grace Period, we may be eligible for an additional 180 calendar day period to regain compliance. To qualify, we would be required to meet the continued listing requirement for the market value of our publicly held shares and all other Nasdaq initial listing standards, with the exception of the bid price requirement, and would need to provide written notice of our intention to cure the deficiency during the second compliance period by effecting a reverse stock split if necessary. However, if it appears to Nasdaq staff that we will not be able to cure the deficiency, or if we do not meet other Nasdaq listing standards, Nasdaq could provide notice that our common stock will be subject to delisting. In the event we receive notice that our common stock is being delisted, we would be entitled to appeal the determination to a Nasdaq Listing Qualifications Panel a